Original language | English (US) |
---|---|
Pages (from-to) | 1631-1643 |
Number of pages | 13 |
Journal | American Journal of Cardiology |
Volume | 102 |
Issue number | 12 |
DOIs |
|
State | Published - Dec 15 2008 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: American Journal of Cardiology, Vol. 102, No. 12, 15.12.2008, p. 1631-1643.
Research output: Contribution to journal › Comment/debate › peer-review
TY - JOUR
T1 - AJC Editor's Consensus
T2 - Psoriasis and Coronary Artery Disease
AU - Friedewald, Vincent E.
AU - Cather, Jennifer C.
AU - Gelfand, Joel M.
AU - Gordon, Kenneth B.
AU - Gibbons, Gary H.
AU - Grundy, Scott M.
AU - Jarratt, Michael T.
AU - Krueger, James G.
AU - Ridker, Paul M.
AU - Stone, Neil
AU - Roberts, William C.
N1 - Funding Information: This CME activity is supported by an educational grant from Amgen, Thousand Oaks, California. Funding Information: Dr. Friedewald has received honoraria for speaking from Novartis, East Hanover, New Jersey. Dr. Cather has received honoraria for speaking, consulting, and board membership from Amgen; Abbott Laboratories, Abbott Park, Illinois; Astellas, Tokyo, Japan; and Genentech, South San Francisco, California. Dr. Gelfand has received consulting fees from Amgen; Genentech; Pfizer, New York, New York; Celgene, Summit, New Jersey; and Centocor, Horsham, Pennsylvania. Dr. Gelfand is a grants investigator for Amgen, Centocor, and Pfizer. Dr. Gordon has received honoraria for consulting and research grants from Abbott and Centocor and honoraria for consulting from Amgen. Dr. Gibbons has received honoraria for speaking from Merck, Whitehouse Station, New Jersey; and Novartis. Dr. Grundy is a consultant for Merck; Merck/Schering-Plough, Kenilworth, New Jersey; Kos, Abbott Park, Illinois; Pfizer; Eli Lilly, Indianapolis, Indiana; GlaxoSmithKline, Research Triangle Park, North Carolina; Abbott Laboratories; Fournier, Chenôve, France; Bristol-Myers Squibb, Plainsboro, New Jersey; Sankyo, Santa Clara, California; AstraZeneca, Wilmington, Delaware; and Sanofi-Aventis, Bridgewater, New Jersey. Dr. Grundy is a research grants investigator for Merck, Abbott, and Kos. Dr. Jarratt is a research grants investigator for Abbott, Amgen, and Genentech. Dr. Krueger has no relevant financial relationships to disclose. Dr. Ridker has received investigator-initiated research grants from the National Heart, Lung, and Blood Institute, Bethesda, Maryland; the National Cancer Institute, Bethesda, Maryland; AstraZeneca; Novartis; Merck; Sanofi-Aventis; the Donald W. Reynolds Foundation, Las Vegas, Nevada; and the Leducq Foundation, Paris, France. Dr. Ridker is a consultant for AstraZeneca; Merck/Schering-Plough; Dade Behring, Deerfield, Illinois; and Isis Pharmaceuticals, Carlsbad, California. Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women's Hospital, Boston, Massachusetts, that relate to the use of inflammatory biomarkers in the detection and treatment of cardiovascular disease. Dr. Stone is a consultant for Abbott; Merck; Schering-Plough; and Unilever, Rotterdam, The Netherlands (donated to American Heart Association). Dr. Stone has received honoraria for educational activities from Abbott, Merck, Pfizer, and Unilever. Dr. Roberts has received honoraria for speaking from Merck/Schering-Plough, AstraZeneca, and Novartis. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2008/12/15
Y1 - 2008/12/15
UR - http://www.scopus.com/inward/record.url?scp=58149477214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149477214&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2008.10.004
DO - 10.1016/j.amjcard.2008.10.004
M3 - Comment/debate
C2 - 19064017
AN - SCOPUS:58149477214
SN - 0002-9149
VL - 102
SP - 1631
EP - 1643
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 12
ER -